Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Statement from FDA Commissioner Scott Gottlieb, M.D., on new policy to improve access and foster price competition for drugs that face inadequate generic competition

“We have been taking new policy steps at the FDA to support downward pressure on drug prices by helping to clear a path for more efficient generic development,” says FDA Commissioner Scott Gottlieb, M.D.

Read More »

Bayer, Janssen and BMS Unveil Promising Data for Prostate Cancer at ASCO GU

At the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU), companies have showcased more clinical data in presentations for prostate cancer treatment.

Read More »

Teva Pharmaceutical sees weaker than expected 2019

Teva Pharmaceutical Industries forecast lower revenue and profit for 2019, missing analysts’ expectations, as the company faces generic competition for two key branded drugs.

Read More »

FDA Approves Split-Dosing Regimen for Darzalex

The U.S. Food and Drug Administration gave Janssen Biotech and the Johnson & Johnson company’s research partner Genmab an approval for their Darzalex split-dosing regimen.

Read More »

Sanofi Cuts 38 R&D Programs to Refocus on Cancer, Immunology, and Rare Diseases

Sanofi reportedly ended 38 R&D programs and is prioritizing oncology, immunology, rare disease and rare blood disorders.

Read More »

Novo Nordisk’s new diabetes drug, outlook lift shares

Novo Nordisk reported solid growth for the company’s new diabetes drug and will submit a tablet version – a key growth hope – for U.S. approval in first-quarter 2019, lifting the Danish drugmaker’s shares.

Read More »

Exclusive: Teva’s generic EpiPen launch stalls months after approval

Many of the largest U.S. pharmacies and drug distributors do not have Teva Pharmaceutical Industries Ltd.’s generic version of EpiPen five months after the life-saving allergy treatment was approved for sale in the United States, pharmacy chains and a group that tracks drug shortages told Reuters.

Read More »

FDA Approves Imbruvica for 10th Time

FDA approved Imbruvica combined with Gazyva for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Read More »

FDA Places Cervical Cancer Study on Clinical Hold

The U.S. Food and Drug Administration placed Princeton, N.J.-based Advaxis’ Phase III clinical trial of axalimogene filolisbac (AXAL) in advanced cervical cancer on partial clinical hold.

Read More »

Yale Researchers Discover Immune System Protein That Can Help Suppress HIV

A new report released by researchers at Yale University could change the way some HIV patients are treated.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom